Agios’ Mitapivat Shows Improvement In Regularly Transfused PKD Patients
Results Follow ACTIVATE Study Data In December
Executive Summary
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.
You may also be interested in...
Agios Sells Cancer Portfolio To Servier To Focus On Genetic Diseases
Agios’ cellular metabolism expertise first delivered cancer drugs but sees greater opportunity in genetically defined diseases. CEO Jackie Fouse talked to Scrip about the business strategy.
Agios’ Phase III Data Move It Closer To First Therapy For Rare Anemia
Strong top-line efficacy in pyruvate kinase deficiency patients who don’t receive regular transfusions looks approvable, analysts say, but Agios will await data in regularly transfused patients.
Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports